Pneumococcal vaccine schedule study for healthy infants
Part of Infections clinical trials.
This study tests the best timing for giving a pneumococcal vaccine (a shot that protects against serious bacterial infections) to healthy 2-month-old babies. Researchers want to find the safest and most effective schedule for this vaccine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is exactly 2 months old (between 60–89 days) at the time of enrollment
- Your baby was born at term (at least 37 weeks pregnancy) and weighed at least 2500 grams (about 5.5 pounds) at birth
- Your baby has never received a pneumococcal vaccine before
- Your baby is healthy with no chronic illnesses, immune problems, or bleeding disorders
- Your baby has no known allergies to vaccine ingredients (including diphtheria or tetanus toxoid)
- You can attend all study visits, keep daily records, and use a thermometer to check your baby's temperature
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This study tests a pneumococcal vaccine (PCV13) in healthy 2-month-old babies to see if it is safe and helps protect against pneumococcal infections. Your baby would receive the vaccine and be monitored for any side effects.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
This study tests an experimental pneumococcal vaccine in healthy infants. It involves three shots during infancy and a booster around 12-15 months to see if it is safe and how the body responds.
Hear when a new Pneumococcal Disease Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.